FDA approves first RSV vaccine for pregnancy to protect newborns
Expectant parents could soon have another new option this fall to protect their newborns from RSV, the most common cause of hospitalization in American infants.
www.cbsnews.comHere are the latest broad updates on RSV vaccines based on recent public reports:
-
FDA approvals and new indications continue to expand. In mid-2025, Moderna’s RSV vaccine mRESVIA received regulatory clearance for additional adult populations beyond older adults, aiming to cover adults under 60 with certain health conditions and supporting use ahead of the 2025/2026 RSV season. This represents progress beyond the initial approvals for older adults and may influence availability for younger cohorts in practice.[1]
-
Existing vaccines remain for at-risk groups. The first RSV vaccines approved in the U.S. (Arexvy for adults 60+, Beyfortus for infants via maternal vaccination) established a baseline of protection against RSV lower respiratory tract disease and severe outcomes, with ongoing post-authorization safety monitoring and refinement of recommendations. The FDA and CDC have continued to update guidance as more real-world data accumulate.[2][3]
-
Maternal vaccination and infant protection remain a policy focus. Pfizer’s maternal RSV vaccine (Abrysvo) was approved to protect newborns through maternal immunization in late 2023, with safety monitoring and postmarketing studies mandated by the FDA to evaluate rare potential risks and ensure timing benefits late in pregnancy. If widely adopted, this approach aims to shield infants during their most vulnerable early months.[3]
-
Safety monitoring continues to evolve. CDC advisories have revisited RSV vaccines with attention to potential adverse events, including rare neurological concerns like Guillain-Barré syndrome, and agencies stress the importance of ongoing safety analyses to refine who should be prioritized for vaccination and how often boosters may be needed. Public guidance emphasizes balancing benefits with rare risks in older adults and other groups.[5]
-
Practical availability and uptake vary by region and year. RSV vaccine uptake and access depend on regulatory decisions, payer coverage, supply chain, and clinician recommendations; several health systems and regions have begun integrating maternal vaccination, adult vaccination for high-risk groups, and seasonal timing into their vaccination programs.[6][8]
If you’d like, I can tailor this to your location (Los Angeles) and pull the most recent local advisories, coverage information, and eligibility guidelines from state and county health departments. I can also summarize key questions you might have for a clinician (e.g., which RSV vaccine is recommended for your age group, timing considerations for pregnancy-related protection, and potential side effects).
Sources:
- Moderna’s RSV vaccine mRESVIA approval updates and expanded age indications.[1]
- FDA and Arexvy/Beyfortus foundational approvals and efficacy data.[2][3]
- CDC/GA guidance updates on RSV vaccine safety and recommendations.[5]
- Maternal RSV vaccination and infant protection policy developments.[3]
- Ongoing uptake and program integration in healthcare systems.[8][6]